The Oregon Health Authority issued a Notice of Proposed Rulemaking for minor edits to the Oregon Health Plan Managed Care Rules. These edits are needed to align with Federal requirements, clarify language, remove outdated references, and correct typos. It also adds a definition for “Plan Type.” Comments are due at 5:00 p.m. on May 21.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
HB 4034, which was signed into law on March 23, includes several provisions of interest including allowing a pharmacy intern to transfer a drug containing pseudoephedrine or ephedrine to a person 18 years of age or older without prescription; reporting of information regarding dispensing of biological products; clarifying the use of telepharmacy and permitting a pharmacist to delegate to a pharmacy technician final verification of prescribed drug and drug dosage, device, or product
Also in Oregon, the Board of Pharmacy has adopted the following rules:
April 22, 2022, Temporary Rules Noticed Pursuant to 2022 HB 4034 (Signed by Gov. Kate Brown (D) on March 23, 2022) – Effective April 22, 2022 through October 18, 2022
The Board also permanently adopted the following rules – effective April 20, 2022 – at the April 2022 Board Meeting:
Finally in Oregon, the Oregon Health Authority issued a temporary rule, effective April 27, 2022, through June 25, 2022, amending prior authorization approval criteria guide effective May 1, 2022. These amendments are based upon Pharmacy & Therapeutics (P&T) Committee recommendations on April 7.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Oregon Health Authority is implementing changes to the Prior Authorization Guide and the Preferred Drug List, including select over-the-counter product classes, to ensure the safe and appropriate use of cost-effective prescription drug for Oregon Health Plan’s fee-for-service recipients. his is a temporary rule effective April 1, 2022, through June 25, 2022.
Also in Oregon, the Oregon Health Authority issued a Notice of Proposed Rulemaking, making permanent changes to the Prior Authorization Guide and the Preferred Drug List, including select over-the-counter product classes, currently in effect as a temporary rule effective April 1, 2022, through June 25, 2022. Comments are due 5:00 p.m. on May 21.
Finally in Oregon, the Board of Pharmacy posted a REVISED agenda and meeting materials for the April 13-15 meeting.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy adopted the following:
Also in Oregon, the Board of Pharmacy posted its agenda and meeting materials for its next meeting scheduled for April 13-15.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy issued its March 2022 newsletter that includes the following articles:
Also in Oregon, as the state enters a new phase of the pandemic, the Oregon Health Authority announced its five-point plan, “Oregon RISE: Resilience in Support of Equity.”
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy proposed to adopt the following rules. Written comments may be submitted via email to pharmacy.rulemaking@bop.oregon.gov before 4:30 p.m. on March 29 rulemaking hearing.
Also in Oregon, the Department of Human Services announced plans to lift mask requirements for indoor public spaces and schools on March 19.
Finally in Oregon, Gov. Kate Brown (D) announced that she will lift the state’s COVID-19 Emergency Declaration effective April 1.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy posted the agenda and meeting materials for the February 9-11, Board Meeting.
Also in Oregon, the Board of Pharmacy issued a notice requesting fiscal impact for Pharmacy Prescription Lockers (PPL) from stakeholders. Note: any information provided to the Board becomes a public record.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy adopted the following permanent rules.
| Permanent Rule | Effective Date |
| Division 007/041/045/065 – related to USP, Labeling, Repackaging | December 16, 2021 |
| Division 010 – related to Board Administration & Policies | December 16, 2021 |
| Division 019/021 – related to Pain Management CE | January 1, 2022 |
| Division 019/139 – related to Remote Dispensing Site Pharmacy/Telepharmacy | January 1, 2022 |
| Division 041 – related to Telework | December 16, 2021 |
| Division 041 – related to TCVP (Technician Checking Validation Program) | October 1, 2022 |
| Division 041/080 – related to Pseudoephedrine/Ephedrine | January 1, 2022 |
| Division 043 – related to SPDO/DPDO/CHC | January 1, 2022 |
| Division 043 – related to SPDO (Supervising Physician Dispensing Outlet) | March 31, 2022 |
| Division 060/110 – related to PDMP Fee Increase | January 1, 2022 |
Also in Oregon, as a reminder, effective January 1, 2022, drugs containing pseudoephedrine and ephedrine may be purchase without a prescription. See item above regarding the permanent rule related to pseudoephedrine/ephedrine. For information about the use of the National Precursor Log Exchange (NPLEx) system, please refer to the Board of Pharmacy’s November 2021 newsletter.
Also in Oregon, the Board of Pharmacy issued a notice requesting fiscal impact estimates from stakeholders for temporary and permanent pharmacy closures. Note: any information provided to the Board becomes a public record.
Finally in Oregon, the Board of Pharmacy’s CE Rules Advisory Committee will meet on January 18. Details to participate in the meeting via phone conference are available in the agenda.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.
The Board of Pharmacy adopted the following permanent rules effective last Friday, December 10.
Also in Oregon, the Board of Pharmacy adopted the following temporary rules effective last Friday, December 10.
For more information, contact NACDS’ Sandra Guckian at 703-774-4801.